China Mobile is just getting on board. I think iphone sales are just getting fired up. Maybe this new competitor that is using android stole some of the thunder in China but I still feel we will see robust sales.
And now we are forced to buy inferior drugs! When does it end?
Thanks Express Scripts! Sell this POS!
Regardless the babies are being thrown out with the bath water here.
You can blame some shortfall on strong U.S. dollar but same store sales in domestic business means they are losing to competition. Wendy's, Burger King, Hardee's are taking market share. The dividend is their only saving grace or it'd be down 20%.
Yes you are right, it looks like around 12/21 is anticipated date. I got this from the Fool article: ..We should have that soon when AbbVie (NYSE: ABBV ) gets its hepatitis C drugs approved by the FDA in December. Enanta Pharmaceuticals will share in the wealth, having helped develop one of the drugs in the cocktail. The PDUFA date for the drugs is Dec. 21, but an approval could come early, especially if FDA reviewers want to clear their desks before the holidays.
While it's always possible the drugs might not get approved, it's highly unlikely. The cocktail is able to rid a vast majority of patients of their hepatitis C virus and appears safe enough to gain approval. The drugs were recently given a positive opinion from the European Committee for Medicinal Products for Human Use. Abbvie just has to wait on the rubber stamp approval from the European Commission before it can launch the drugs, which will go by Viekirax and Exviera, in Europe.
Once approved, Viekirax and Exviera will compete with Gilead Sciences' (NASDAQ: GILD ) Harvoni. As a single pill taken once a day, Harvoni has the clear advantage over Abbvie's regimen, which requires two pills, one of which has to be taken twice a day. AbbVie might be able to capture some of the market share if it discounts its combination enough to get health insurers to make its cocktail the preferred (or perhaps only) hepatitis C drugs covered by the insurance plan.
I'm hoping this won't retreat! Keeping my fingers crossed! 105 now!
I'd like to see a little more volume but I guess some would say it isn't necessary. I just pulled up a 12/4 analyst report however that states 26 analyst average target is $130 and the PEG currently is .66 so at these prices it definitely isn't over-valued. Sentiment is bullish. Only negativity has been the ABBV overhang which should end 12/15. Earnings isn't until February and I did hear that the analysts weren't "WOW'D" with the last report. Would like to hear more positive feedback from management but there sure are helluva worse buys out there.
Egggsakly. Institutions aren't going to rush in either until the ABBV ruling is over and done. Makes it easy to manipulate here.
This is good news for GILD.